Antibodies that bind IL-4 and/or IL-13 and their uses

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8388965
APP PUB NO 20100226923A1
SERIAL NO

12682864

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SANOFI46 AVENUE DE LA GRANDE ARMÉE PARIS 75017

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Davison, Matthew Long Valley, US 24 224
Kruip, Jochen Erzhausen, DE 38 282
Li, Danxi Skillman, US 60 408
Mikol, Vincent Charenton-le-Pont, FR 48 606
Rao, Ercole Morfelden-Walldorf, DE 57 481

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 5, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00